to provide a pre-planned protocol. The Baird study 3 additionally presented effect size estimates for outcome metrics based on undisclosed data, preventing basic reproduction of the computation procedures that produced these estimates. Critically, the transparent and consistent reporting of the number of analyses performed, and justification for why certain outcomes were selected and presented, are needed for methods reproducibility. The Baird study 3 also failed to meet this standard, with outcomes dropped between different versions of the same article. Standards of results reproducibility and inferential reproducibility are also violated by the several studies reviewed. In two replication studies 4,5 using the same data and/or analytical approach as the original Kenya trial, 6 the subsequent authors found errors and noted that the previously claimed results were not observed. Rndom errors are possible, but it is difficult to understand why the results differed without adequate information on how the analyses were conducted. When study design, definitions, outcomes and analytical methods are unclear or altered across various reports, individual research findings are less likely to be true. 7 If we think of research reproducibility through a Bayesian lens, the goal of repeating studies is to increase the amount of total available evidence that either supports or does not support the claims made by previous studies. If a hypothesis being tested has a low prior probability, a considerable amount of high-quality evidence is necessary to change the a priori reasoning. 2 In this case, all three deworming studies appraised by Jullien et al. 1 either selectively reported or failed to report some outcomes, which makes it difficult for subsequent authors to draw the same conclusions from either the original data or from newly collected data. We thank all the reviewers for their comments and insights. Our aim when conducting this appraisal was for the findings of studies to be discussed in the context of their reliability, rather than simply quoted. This discussion is now happening, and readers and policy makers are free to reach their own informed conclusions. As independent researchers with over 22 years of experience in evidence appraisal, we value transparency in
tionally presented effect size estimates for outcome metrics based on undisclosed data, preventing basic reproduction of the computation procedures that produced these estimates. Critically, the transparent and consistent reporting of the number of analyses performed, and justification for why certain outcomes were selected and presented, are needed for methods reproducibility. The Baird study 3 also failed to meet this standard, with outcomes dropped between different versions of the same article.
Standards of results reproducibility and inferential reproducibility are also violated by the several studies reviewed. In two replication studies 4, 5 using the same data and/or analytical approach as the original Kenya trial, 6 the subsequent authors found errors and noted that the previously claimed results were not observed. Rndom errors are possible, but it is difficult to understand why the results differed without adequate information on how the analyses were conducted. When study design, definitions, outcomes and analytical methods are unclear or altered across various reports, individual research findings are less likely to be true. 7 If we think of research reproducibility through a Bayesian lens, the goal of repeating studies is to increase the amount of total available evidence that either supports or does not support the claims made by previous studies. If a hypothesis being tested has a low prior probability, a considerable amount of high-quality evidence is necessary to change the a priori reasoning. 2 In this case, all three deworming studies appraised by Jullien et al. 1 either selectively reported or failed to report some outcomes, which makes it difficult for subsequent authors to draw the same conclusions from either the original data or from newly collected data.
The paradigm proposed by Goodman et al. 2 provides a framework for epidemiologists who seek to produce rigorously reproducible studies. We would argue that when viewing epidemiological studies through this framework, we should not only focus on cumulative evidence instead of on individual significance tests, but should also focus on designing our own research with methods, results and inferential reproducibility in mind.
deriving the expected benefits and harms of an intervention; in estimating the size of the effects; and in assessing the level of certainty that these estimates are correct. With community deworming programmes we consider this transparency important for both the children and parents participating in the programmes, and the governments and philanthropists funding them. A recurring theme of the commentaries is that whereas some of our criticisms stand up and are important, others might be considered over-critical or of limited importance. Nevertheless, when put together we would consider there to be very low certainty in the evidence provided by these three trials.
It seems obvious to us that there is probably too much uncertainty to justify their promotion as educational or economic interventions: the study by Baird et al.
1,2 primarily suffers from repeated, iterative analyses which, without a pre-stated primary analysis, are highly susceptible to selective reporting and interpretation. The study by Ozier 2,3 has more consistent results in children not dewormed but living in deworming areas, but we struggle with the plausibility of these effects when so many trials of more direct and intensive interventions have failed to demonstrate any effects on intermediate outcomes along the presumed causal pathways. With the study by Croke 2,4 there is so much uncertainty about the impact of such a large loss of data (over half the original clusters), and the relationship between the 763 included children and the 27 995 children in the original study, that it is probably misleading to consider it a randomized experiment. The most common defence against criticism of community deworming programmes is that they are simply a more cost-effective way of reaching infected children than a policy of 'screen and treat'. Although this may be true, both the long-standing Cochrane Review and the recently completed independent Campbell Review conclude that there is no reliable evidence of community-level effects beyond a short-term reduction in the prevalence of intestinal worms. 1, 2 We have for some years provided independent critical appraisals and summaries of evidence to help guide policy on a broad range of health interventions relevant to lowand middle-income countries. When we find high quality evidence of consistent benefits, these summaries are welcomed and used by advocates to accelerate the adoption of policies; but when we find the evidence base for existing policies to be weak or inconsistent, the summaries are often attacked or ignored. How the development community now advance with this appraisal we will watch with interest.
More broadly, we hope this debate will strengthen research and analytical methods in development economics, so that the economic and epidemiological disciplines move forward together with a stronger scientific base underpinning the research, its appraisal and whether and how it is used to inform policy.
